Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy

Bor-Shyang Sheu, Hsiu-Chi Cheng, Ai Wen Kao, Shan-Tair Wang, Yao-jong Yang, Hsiao Bai Yang, Jiunn Jong Wu

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Background: Lactobacillus- and Bifidobacterium-containing yogurt (AB-yogurt) can suppress Helicobacter pylori. Improvement of the eradication rate by quadruple therapy of residual H. pylori after failed triple therapy is needed. Objective: We tested whether prior treatment with AB-yogurt improved the efficacy of quadruple therapy in eradicating residual H. pylori after failed triple therapy. Design: One hundred thirty-eight patients in whom triple therapy failed were enrolled for a culture study of H. pylori to assess antimicrobial resistance. These patients were then randomly assigned in equal numbers to either a yogurt-plus-quadruple therapy group or a quadruple therapy-only group. The patients received 1 wk of quadruple therapy with or without a 4-wk pretreatment with AB-yogurt (400 mL/d). In the yogurt-plus-quadruple group, excessive δ13CO2/mL values of the 13C-urea breath test were collected before and every 2 wk during the 4-wk ingestion of yogurt. For both groups, a 13C-urea breath test was conducted ≥6 wk after the quadruple therapy to assess the outcome of residual H. pylori eradication. Results: For the patients in the yogurt-plus-quadruple therapy group infected with either antibiotic-sensitive or -resistant H. pylori, the excessive δ13CO2/mL values of the 13C-urea breath test were significantly decreased after the 4-wk ingestion of AB-yogurt (P < 0.0001). The yogurt-plus-quadruple therapy group had a higher H. pylori eradication rate than did the quadruple therapy-only group (intention-to-treat analysis: 85% compared with 71.1%, P < 0.05; per-protocol analysis: 90.8% compared with 76.6%, P < 0.05). Conclusion: A 4-wk pretreatment with AB-yogurt can decrease H. pylori loads despite antimicrobial resistance, thus improving the efficacy of quadruple therapy in eradicating residual H. pylori.

Original languageEnglish
Pages (from-to)864-869
Number of pages6
JournalAmerican Journal of Clinical Nutrition
Volume83
Issue number4
Publication statusPublished - 2006 Apr 1

Fingerprint

Yogurt
Bifidobacterium
Helicobacter Infections
Lactobacillus
Helicobacter pylori
Group Psychotherapy
Breath Tests
Therapeutics
Urea
Eating
Intention to Treat Analysis
Anti-Bacterial Agents

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

@article{f974ce431c1b4dd18d8ff1251d8f65a5,
title = "Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy",
abstract = "Background: Lactobacillus- and Bifidobacterium-containing yogurt (AB-yogurt) can suppress Helicobacter pylori. Improvement of the eradication rate by quadruple therapy of residual H. pylori after failed triple therapy is needed. Objective: We tested whether prior treatment with AB-yogurt improved the efficacy of quadruple therapy in eradicating residual H. pylori after failed triple therapy. Design: One hundred thirty-eight patients in whom triple therapy failed were enrolled for a culture study of H. pylori to assess antimicrobial resistance. These patients were then randomly assigned in equal numbers to either a yogurt-plus-quadruple therapy group or a quadruple therapy-only group. The patients received 1 wk of quadruple therapy with or without a 4-wk pretreatment with AB-yogurt (400 mL/d). In the yogurt-plus-quadruple group, excessive δ13CO2/mL values of the 13C-urea breath test were collected before and every 2 wk during the 4-wk ingestion of yogurt. For both groups, a 13C-urea breath test was conducted ≥6 wk after the quadruple therapy to assess the outcome of residual H. pylori eradication. Results: For the patients in the yogurt-plus-quadruple therapy group infected with either antibiotic-sensitive or -resistant H. pylori, the excessive δ13CO2/mL values of the 13C-urea breath test were significantly decreased after the 4-wk ingestion of AB-yogurt (P < 0.0001). The yogurt-plus-quadruple therapy group had a higher H. pylori eradication rate than did the quadruple therapy-only group (intention-to-treat analysis: 85{\%} compared with 71.1{\%}, P < 0.05; per-protocol analysis: 90.8{\%} compared with 76.6{\%}, P < 0.05). Conclusion: A 4-wk pretreatment with AB-yogurt can decrease H. pylori loads despite antimicrobial resistance, thus improving the efficacy of quadruple therapy in eradicating residual H. pylori.",
author = "Bor-Shyang Sheu and Hsiu-Chi Cheng and Kao, {Ai Wen} and Shan-Tair Wang and Yao-jong Yang and Yang, {Hsiao Bai} and Wu, {Jiunn Jong}",
year = "2006",
month = "4",
day = "1",
language = "English",
volume = "83",
pages = "864--869",
journal = "American Journal of Clinical Nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "4",

}

TY - JOUR

T1 - Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy

AU - Sheu, Bor-Shyang

AU - Cheng, Hsiu-Chi

AU - Kao, Ai Wen

AU - Wang, Shan-Tair

AU - Yang, Yao-jong

AU - Yang, Hsiao Bai

AU - Wu, Jiunn Jong

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Background: Lactobacillus- and Bifidobacterium-containing yogurt (AB-yogurt) can suppress Helicobacter pylori. Improvement of the eradication rate by quadruple therapy of residual H. pylori after failed triple therapy is needed. Objective: We tested whether prior treatment with AB-yogurt improved the efficacy of quadruple therapy in eradicating residual H. pylori after failed triple therapy. Design: One hundred thirty-eight patients in whom triple therapy failed were enrolled for a culture study of H. pylori to assess antimicrobial resistance. These patients were then randomly assigned in equal numbers to either a yogurt-plus-quadruple therapy group or a quadruple therapy-only group. The patients received 1 wk of quadruple therapy with or without a 4-wk pretreatment with AB-yogurt (400 mL/d). In the yogurt-plus-quadruple group, excessive δ13CO2/mL values of the 13C-urea breath test were collected before and every 2 wk during the 4-wk ingestion of yogurt. For both groups, a 13C-urea breath test was conducted ≥6 wk after the quadruple therapy to assess the outcome of residual H. pylori eradication. Results: For the patients in the yogurt-plus-quadruple therapy group infected with either antibiotic-sensitive or -resistant H. pylori, the excessive δ13CO2/mL values of the 13C-urea breath test were significantly decreased after the 4-wk ingestion of AB-yogurt (P < 0.0001). The yogurt-plus-quadruple therapy group had a higher H. pylori eradication rate than did the quadruple therapy-only group (intention-to-treat analysis: 85% compared with 71.1%, P < 0.05; per-protocol analysis: 90.8% compared with 76.6%, P < 0.05). Conclusion: A 4-wk pretreatment with AB-yogurt can decrease H. pylori loads despite antimicrobial resistance, thus improving the efficacy of quadruple therapy in eradicating residual H. pylori.

AB - Background: Lactobacillus- and Bifidobacterium-containing yogurt (AB-yogurt) can suppress Helicobacter pylori. Improvement of the eradication rate by quadruple therapy of residual H. pylori after failed triple therapy is needed. Objective: We tested whether prior treatment with AB-yogurt improved the efficacy of quadruple therapy in eradicating residual H. pylori after failed triple therapy. Design: One hundred thirty-eight patients in whom triple therapy failed were enrolled for a culture study of H. pylori to assess antimicrobial resistance. These patients were then randomly assigned in equal numbers to either a yogurt-plus-quadruple therapy group or a quadruple therapy-only group. The patients received 1 wk of quadruple therapy with or without a 4-wk pretreatment with AB-yogurt (400 mL/d). In the yogurt-plus-quadruple group, excessive δ13CO2/mL values of the 13C-urea breath test were collected before and every 2 wk during the 4-wk ingestion of yogurt. For both groups, a 13C-urea breath test was conducted ≥6 wk after the quadruple therapy to assess the outcome of residual H. pylori eradication. Results: For the patients in the yogurt-plus-quadruple therapy group infected with either antibiotic-sensitive or -resistant H. pylori, the excessive δ13CO2/mL values of the 13C-urea breath test were significantly decreased after the 4-wk ingestion of AB-yogurt (P < 0.0001). The yogurt-plus-quadruple therapy group had a higher H. pylori eradication rate than did the quadruple therapy-only group (intention-to-treat analysis: 85% compared with 71.1%, P < 0.05; per-protocol analysis: 90.8% compared with 76.6%, P < 0.05). Conclusion: A 4-wk pretreatment with AB-yogurt can decrease H. pylori loads despite antimicrobial resistance, thus improving the efficacy of quadruple therapy in eradicating residual H. pylori.

UR - http://www.scopus.com/inward/record.url?scp=33646693155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646693155&partnerID=8YFLogxK

M3 - Article

C2 - 16600940

AN - SCOPUS:33646693155

VL - 83

SP - 864

EP - 869

JO - American Journal of Clinical Nutrition

JF - American Journal of Clinical Nutrition

SN - 0002-9165

IS - 4

ER -